Enveric Biosciences (Enveric Biosciences) Operating Cash Flow per Share : $-6.62 (TTM As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Enveric Biosciences Operating Cash Flow per Share?

Enveric Biosciences's operating cash flow per share for the three months ended in Dec. 2023 was $-0.77. Enveric Biosciences's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-6.62.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 42.20% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 58.70% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 36.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Enveric Biosciences's Operating Cash Flow per Share or its related term are showing as below:

ENVB' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -121.9 Med: 37.2 Max: 66.7
Current: 42.2

During the past 13 years, Enveric Biosciences's highest 3-Year average Operating Cash Flow per Share Growth Rate was 66.70% per year. The lowest was -121.90% per year. And the median was 37.20% per year.

ENVB's 3-Year OCF Growth Rate is ranked better than
86.78% of 1241 companies
in the Biotechnology industry
Industry Median: 3.8 vs ENVB: 42.20

Enveric Biosciences Operating Cash Flow per Share Historical Data

The historical data trend for Enveric Biosciences's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enveric Biosciences Operating Cash Flow per Share Chart

Enveric Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-223.00

-33.82

-24.28

-11.86

-6.53

Enveric Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Operating Cash Flow per Share	Get a 7-Day Free Trial															-1.66	-2.47	-2.12	-1.27	-0.77

Competitive Comparison of Enveric Biosciences's Operating Cash Flow per Share

For the Biotechnology subindustry, Enveric Biosciences's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enveric Biosciences's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enveric Biosciences's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Enveric Biosciences's Price-to-Operating-Cash-Flow falls into.

Enveric Biosciences Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Enveric Biosciences's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-14.094	/	2.159
	=	-6.53

Enveric Biosciences's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	-1.751	/	2.285
	=	-0.77

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.62

Enveric Biosciences Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Enveric Biosciences's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Enveric Biosciences (Enveric Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enveric Biosciences Inc (NAS:ENVB) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

SLZA:Germany

Address

4851 Tamiami Trail N, Suite 200, Naples, FL, USA, 34103

Website

https://www.enveric.com

Enveric Biosciences Inc is a patient-centric biotechnology company focused on developing new-generation, naturally occurring chemical compounds, such as cannabinoids to improve the lives of those who are adversely affected by the side effects of cancer treatments. Its product in the pipeline includes Glioblastoma Multiforme (GBM); Radiation Dermatitis and Chemotherapy-Induced Peripheral Neuropathy (CIPN).

Executives

Frank Pasqualone	director	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Kevin Michael Coveney	officer: Chief Financial Officer	10 CLEVELAND ST, A, SOMERVILLE MA 02143-2606
Robert Iv Dickey	officer: Chief Financial Officer	320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Bevin O'neil	director	C/O ENVERIC BIOSCIENCES, INC.,, 4851 TAMIAMI TRAIL N, SUITE 200, NAPLES FL 34103
Michael D Webb	director	C/O EPIX MEDICAL INC, 71 ROGERS ST, CAMBRIDGE MA 02142
Bradley George Thompson	director	1646 ACTON AVE. SW, CALGARY, ALBERTA Z4 T2T 2P9
Jillian Marie Hagel	officer: Chief Technical Officer	3655 36 ST NW, CALGARY, AB Z4 T2L 1Y8
Joseph Edward Tucker	director, officer: Chief Executive Officer	3655 36 ST NW, CALGARY, AB, Z4 T2L 1Y8
Peter J. Facchini	officer: Chief Scientific Officer	155 RANCHRIDGE DRIVE NW, CALGARY, ALBERTA Z4 T3G 1W1
Carter Julian Ward	officer: Chief Financial Officer	165 LUDLOW AVE., NORTHVALE NJ 07647
Douglas Lind	director
Marcus Schabacker	director	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Solomon Mayer	director	150 CENTRAL PARK SOUTH 2ND FLOOR, NEW YORK NY 10019
David Ian Johnson	director, officer: CEO and Chairman	C/O ALLIQUA, INC., 850 3RD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Robert G. Wilkins	officer: Chief Medical Officer	C/O JAY PHARMA INC., 4851 TAMIAMI TRAIL N, SUITE 200, NAPLES FL 34103